FindTrial
Sign In

-TT:14

2 trials

Sponsors

GlaxoSmithKline Biologicals

Conditions

A three-dose primary vaccination of healthy infants between 9-16 weeks (63-118 days) of age at the time of the first vaccination against Streptococcus pneumoniae.Two doses vaccination in adults subjects aged between 18 and 40 years old, in good general health and not previously immunized with the 23-valent pneumococcal polysaccharide vaccine.

Phase 1

An open, phase I/II study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ 11PCV combined with adjuvant AS02V given as a 2-dose vaccination in adults aged 18-40 years old. - EXPLO-CRD-006
Active, not recruitingEUCTR2006-000442-39-BE
GlaxoSmithKline BiologicalsTwo doses vaccination in adults subjects aged between 18 and 40 years old, in good general health and not previously immunized with the 23-valent pneumococcal polysaccharide vaccine.
Start: 2006-04-12Target: 10Updated: 2022-03-28

Phase 3

A phase IIIb randomized, open, controlled study to assess the effect of prophylactic antipyretic treatment on the rate of febrile reactions following concomitant administration of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine with GSK Biologicals’ Infanrix hexa vaccine in children at 3, 4 and 5 months of age and GSK Biologicals’ Rotarix vaccine at 3 and 4 months of age. - 10PN-PD-DIT-010
Active, not recruitingEUCTR2006-000559-16-CZ
GlaxoSmithKline BiologicalsA three-dose primary vaccination of healthy infants between 9-16 weeks (63-118 days) of age at the time of the first vaccination against Streptococcus pneumoniae.
Start: 2006-08-09Target: 460Updated: 2022-04-04